Market Overview

Benzinga's Top Upgrades, Downgrades For December 24, 2019

Share:

Downgrades

  • B. Riley downgraded AquaVenture Holdings Limited (NYSE: WAAS) from Buy to Neutral. AquaVenture shares closed at $27.10 on Monday.
  • Argus Research downgraded FedEx Corporation (NYSE: FDX) from Buy to Hold. FedEx shares closed at $151.69 on Monday.
  • Jefferies downgraded Wright Medical Group N.V. (NASDAQ: WMGI) from Buy to Hold. Wright Medical shares closed at $30.26 on Monday.
  • Raymond James downgraded AquaVenture Holdings (NYSE: WAAS) from Outperform to Market Perform. AquaVenture shares closed at $27.10 on Monday.
  • RBC Capital downgraded AquaVenture Holdings Limited (NYSE: WAAS) from Outperform to Sector Perform. AquaVenture shares closed at $27.10 on Monday.
  • Lake Street downgraded AquaVenture Holdings Limited (NYSE: WAAS) from Buy to Hold. AquaVenture shares closed at $27.10 on Monday.

Initiations

  • Oppenheimer initiated coverage on MannKind Corporation (NASDAQ: MNKD) with an Outperform rating. MannKind closed at $1.31 on Monday.
  • Analysts at Raymond James initiated coverage on Amgen Inc. (NASDAQ: AMGN) with a Market Perform rating. Amgen shares closed at $243.03 on Monday.
  • JP Morgan initiated coverage on Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) with an Overweight rating. The price target for Y-mAbs Therapeutics is set to $39. Y-mAbs Therapeutics shares closed at $32.42 on Monday.
  • Analysts at Cantor Fitzgerald initiated coverage on Stemline Therapeutics, Inc. (NASDAQ: STML) with an Overweight rating. The price target for Stemline Therapeutics is set to $18. Stemline Therapeutics shares closed at $10.77 on Monday.
  • Analysts at Raymond James initiated coverage on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) with a Market Perform rating. Regeneron Pharmaceuticals shares closed at $374.20 on Monday.
  • JP Morgan initiated coverage on Kodiak Sciences Inc. (NASDAQ: KOD) with an Overweight rating. The price target for Kodiak Sciences is set to $82. Kodiak Sciences shares closed at $66.10 on Monday.
  • Analysts at Oppenheimer initiated coverage on Otonomy, Inc. (NASDAQ: OTIC) with a Outperform rating. The price target for Otonomy is set to $8. Otonomy shares closed at $2.55 on Monday.

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

 

Related Articles (AMGN + FDX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SNPSCFRAMaintains160.0
GRPNMorgan StanleyMaintains1.5
PPCCFRADowngrades30.0
HMSYCantor FitzgeraldReiterates33.0
FSLRCascendMaintains60.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com